Results 191 to 200 of about 278,963 (360)

Considerations for Neural Cannabis Cue-Reactivity Studies in Individuals With Cannabis Use Disorder. [PDF]

Biol Psychiatry Glob Open Sci
Grodin EN, McManus K.
europepmc   +1 more source

Medicinal use of cannabis based products and cannabinoids [PDF]

, 2019
Tom P. Freeman, Chandni Hindocha, Sebastian F Green, Michael Bloomfield   +3 more
openalex   +1 more source

Cannabis Indica [PDF]

BMJ, 1883
openaire   +2 more sources

A cost–benefit analysis of the implementation and scale‐up of harm reduction interventions in the Australian Capital Territory

Addiction, EarlyView.
Abstract Background and aims Harm reduction interventions aim to reduce negative consequences of drug use. We aimed to estimate the cost, health impact and economic benefits of current, expanded and new harm reduction interventions for people who use drugs in the Australian Capital Territory.
Anna L. Bowring, Tom Tidhar, Anna Olsen, Christopher Bailie, Kelvin Burke, Rowan Martin‐Hughes, Helen Keane, Paul Dietze, Nick Scott   +8 more
wiley   +1 more source

From symptoms to mechanisms: multidimensional insights into cannabis smoke. [PDF]

Eur Respir J
Liu C, Zhu Z.
europepmc   +1 more source

The effects of cannabis use on physical and mental health

, 2012
Jan C. van Ours, Jenny Williams
openalex   +2 more sources

Risk Perceptions about Cannabis Use and Receipt of Health-Related Information during Pregnancy

, 2022
Lara B. McKenzie, Sarah A. Keim, Mark A. Klebanoff   +2 more
openalex   +2 more sources

Detecting cannabis use reduction through biochemical verification of urinary cannabinoids: An aggregated analysis of cannabis use disorder treatment trials examining average reductions and individual cut‐points

Addiction, EarlyView.
Abstract Background and aims Currently, there is no data‐driven cannabis reduction metric using biochemical verification, which represents a significant gap in cannabis harm reduction research, treatment and policy. Using aggregated data from 7 cannabis use disorder treatment trials, the aims of this analysis were to 1) determine if decreases in self ...
Erin A. McClure, Brian Neelon, Rachel L. Tomko, Ashley Dowd, Kevin M. Gray, Aimee L. McRae‐Clark, Nathaniel Baker   +6 more
wiley   +1 more source

Varenicline for cannabis use disorder: A randomized controlled trial

Addiction, EarlyView.
Abstract Background and aims Although cannabis use is widespread and prevalence of cannabis use disorder (CUD) is increasing, limited advancements have been made in CUD medication development. The objective of this study was to test the efficacy of varenicline with medical management for reducing cannabis use in treatment‐seeking individuals with CUD ...
Aimee L. McRae‐Clark, Kevin M. Gray, Nathaniel L. Baker, Brian J. Sherman, Bryan Tolliver, Jessica Burt, Alonzo Steplight, Elizabeth Chapman, Amanda Wagner   +8 more
wiley   +1 more source

A qualitative study of same session co-use of nicotine and cannabis among adolescents and young adults. [PDF]

PLoS One
Davis DR, Cavallo DA, Bold KW, Morean ME, Kong G, Li W, Ponte V, Franco N, Lichenstein S, Krishnan-Sarin S.   +9 more
europepmc   +1 more source